Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Martin

Showing results (221-230 of 278) with videos related to

Pageof 28
Sort By:
The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 24, 2023
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE<sup>B</sup> studyJosé Angel García-Sáenz, Frederik Marmé, Michael Untch, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Frontiers in Oncology|September 22, 2022
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trialKatya Galactionova, Sibylle Loibl, Paola Salari, et al.
NPJ Precision Oncology|August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibZhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
Pageof 28

Showing results (221-230 of 278) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 24, 2023
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE<sup>B</sup> studyJosé Angel García-Sáenz, Frederik Marmé, Michael Untch, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Frontiers in Oncology|September 22, 2022
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trialKatya Galactionova, Sibylle Loibl, Paola Salari, et al.
NPJ Precision Oncology|August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibZhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
Pageof 28